MAXCYTE, INC. 8-K

What Happened
MaxCyte, Inc. (MXCT) filed an 8-K on March 20, 2026, disclosing that Nasdaq's Listing Qualifications staff sent a notice saying the company's closing bid price fell below $1.00 per share for 30 consecutive trading days, triggering noncompliance with Nasdaq Listing Rule 5450(a)(1). The notice does not immediately delist the stock, and shares continue to trade on the Nasdaq Global Select Market.

Key Details

• Nasdaq provided an initial 180-calendar-day compliance period, giving MaxCyte until September 14, 2026, to regain compliance.
• To cure the deficiency, the closing bid price must be at least $1.00 per share for a minimum of 10 consecutive trading days before September 14, 2026.
• If not regained, MaxCyte may apply to transfer from the Nasdaq Global Select Market to the Nasdaq Capital Market and, if eligible, receive an additional 180-day compliance period (subject to meeting other listing standards and Nasdaq review).
• The company may appeal any delisting determination; the stock would remain listed during the appeal process. The 8-K was signed by Douglas Swirsky, Chief Financial Officer.

Why It Matters
For investors, this notice signals a risk that MaxCyte could face delisting if the share price does not meet Nasdaq's minimum bid requirement. Continued listing status affects liquidity, institutional ownership, and access to capital; while trading is continuing now, failure to regain compliance could lead to transfer to a different Nasdaq market or potential delisting (subject to appeal). The filing gives a clear timeline and objective metric ($1.00 for 10 consecutive days) that investors can monitor.